Clik here to view.
BioLight in pact to maximize presence in China
BioLight Life Sciences Investments (OTC:BLGTY; TASE:BOLT) has entered into a strategic partnership with Rock-One International Holdings of China to maximize its presence in the Chinese market. Rock-One...
View ArticleClik here to view.
BioLight in DES diagnostic collaboration with Ora
BioLight Life Sciences Investments (OTCQX:BLGTY; TASE:BOLT) has expanded its relationship with Ora Inc., with the signing of a collaboration agreement to advance the clinical, regulatory and commercial...
View ArticleClik here to view.
BioLight obtains CE Mark for CellDetect test
BioLight Life Sciences Investments’ (OTC:BLGTY; TASE:BOLT) CellDetect non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in...
View ArticleClik here to view.
BioLight in joint financing accord for IOPtima unit
BioLight Life Sciences Investments (OTCQX:BLGTY; TASE:BOLT) and two Asia-based venture capital firms have entered into a joint financing agreement for a direct equity investment in BioLight’s IOPtima...
View ArticleClik here to view.
BioLight, Axella to advance CellDetect in bladder cancer
BioLight Life Sciences Investments’ (OTCQX:BLGTY; TASE:BOLT) cancer diagnostics subsidiary, Micromedic Technologies (TASE:MCTC), has entered into a collaboration agreement with Axella Research to...
View ArticleClik here to view.
BioLight Life Sciences focusing on ophthalmic portfolio
BioLight Life Sciences Investments (OTCQX:BLGTY; TASE:BOLT) is now defining itself as an ophthalmology company after spending several years assembling a cluster of investments in the sector as well as...
View ArticleClik here to view.
Canada clears BioLight’s IOPtiMate system
The Canadian Medical Devices Bureau has approved BioLight Life Sciences Investments’ (OTCQX:BLGTY; TASE:BOLT) IOPtiMate system for the treatment of glaucoma, allowing the company to commercialize the...
View ArticleClik here to view.
BioLight reports positive TeaRx test results for DES
BioLight Israeli Life Sciences Investments (OTCQX: BLGTY; TASE: BOLT) has completed a second successful U.S. clinical study to assess the effectiveness of its TeaRx multi-assay test in evaluating...
View ArticleClik here to view.
BioLight makes first IOPtiMate sale in Hungary
BioLight Life Sciences Investments (OTCQX:BLGTY; TASE:BOLT) has announced the first sale of the IOPtiMate system to a medical center in Hungary. The IOPtiMate system is based on CO2 laser technology...
View ArticleClik here to view.
BioLight expands portfolio with eye drops for DES
BioLight Life Sciences (TASE:BOLT) has obtained worldwide rights, excluding Israel and Italy, for the manufacturing, distribution, sales and marketing of a groundbreaking new eye drop product for the...
View Article
